PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The use of nanosecond pulsed electric fields to ablate tumors (nanoelectroablation) is now well established in the murine xenograft model system. In order bring this therapy into the clinic for the treatment of human tumors we are developing both a pulse generator as well as delivery electrodes to target the tumors to be treated. We will describe the PulseCure® Model MBR-1 100 ns pulse generator and the first human clinical trial data using nanoelectroablation to scarlessly ablate basal cell carcinomas.
Richard Nuccitelli,Mark Kreis,Brian Athos,Ryan Wood,Joanne Huynh,Kaying Lui,Pamela Nuccitelli, andErvin Epstein
"Nanoelectroablation for human carcinoma therapy", Proc. SPIE 8585, Terahertz and Ultrashort Electromagnetic Pulses for Biomedical Applications, 85850G (23 February 2013); https://doi.org/10.1117/12.2002538
The alert did not successfully save. Please try again later.
Richard Nuccitelli, Mark Kreis, Brian Athos, Ryan Wood, Joanne Huynh, Kaying Lui, Pamela Nuccitelli, Ervin Epstein, "Nanoelectroablation for human carcinoma therapy," Proc. SPIE 8585, Terahertz and Ultrashort Electromagnetic Pulses for Biomedical Applications, 85850G (23 February 2013); https://doi.org/10.1117/12.2002538